Axsome Therapeutics Stock Market Value
| AXSM Stock | USD 182.94 3.27 1.76% |
| Symbol | Axsome |
Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.66) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Axsome Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Axsome Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Axsome Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Axsome Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Axsome Therapeutics or generate 0.0% return on investment in Axsome Therapeutics over 90 days. Axsome Therapeutics is related to or competes with Nuvalent, Abivax SA, Cytokinetics, Rhythm Pharmaceuticals, Arrowhead Pharmaceuticals, Crispr Therapeutics, and Vaxcyte. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervou... More
Axsome Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Axsome Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Axsome Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.69 | |||
| Information Ratio | 0.1151 | |||
| Maximum Drawdown | 26.78 | |||
| Value At Risk | (2.46) | |||
| Potential Upside | 4.2 |
Axsome Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Axsome Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Axsome Therapeutics' standard deviation. In reality, there are many statistical measures that can use Axsome Therapeutics historical prices to predict the future Axsome Therapeutics' volatility.| Risk Adjusted Performance | 0.1233 | |||
| Jensen Alpha | 0.503 | |||
| Total Risk Alpha | 0.0843 | |||
| Sortino Ratio | 0.2286 | |||
| Treynor Ratio | (1.96) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Axsome Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Axsome Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1233 | |||
| Market Risk Adjusted Performance | (1.95) | |||
| Mean Deviation | 1.82 | |||
| Semi Deviation | 1.34 | |||
| Downside Deviation | 1.69 | |||
| Coefficient Of Variation | 685.37 | |||
| Standard Deviation | 3.36 | |||
| Variance | 11.28 | |||
| Information Ratio | 0.1151 | |||
| Jensen Alpha | 0.503 | |||
| Total Risk Alpha | 0.0843 | |||
| Sortino Ratio | 0.2286 | |||
| Treynor Ratio | (1.96) | |||
| Maximum Drawdown | 26.78 | |||
| Value At Risk | (2.46) | |||
| Potential Upside | 4.2 | |||
| Downside Variance | 2.86 | |||
| Semi Variance | 1.79 | |||
| Expected Short fall | (2.26) | |||
| Skewness | 4.57 | |||
| Kurtosis | 29.75 |
Axsome Therapeutics Backtested Returns
Axsome Therapeutics appears to be very steady, given 3 months investment horizon. Axsome Therapeutics secures Sharpe Ratio (or Efficiency) of 0.15, which signifies that the company had a 0.15 % return per unit of risk over the last 3 months. By analyzing Axsome Therapeutics' technical indicators, you can evaluate if the expected return of 0.53% is justified by implied risk. Please makes use of Axsome Therapeutics' Mean Deviation of 1.82, downside deviation of 1.69, and Risk Adjusted Performance of 0.1233 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Axsome Therapeutics holds a performance score of 12. The firm shows a Beta (market volatility) of -0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Axsome Therapeutics are expected to decrease at a much lower rate. During the bear market, Axsome Therapeutics is likely to outperform the market. Please check Axsome Therapeutics' maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to make a quick decision on whether Axsome Therapeutics' price patterns will revert.
Auto-correlation | 0.38 |
Below average predictability
Axsome Therapeutics has below average predictability. Overlapping area represents the amount of predictability between Axsome Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Axsome Therapeutics price movement. The serial correlation of 0.38 indicates that just about 38.0% of current Axsome Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.38 | |
| Spearman Rank Test | 0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 95.34 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Axsome Therapeutics Correlation, Axsome Therapeutics Volatility and Axsome Therapeutics Performance module to complement your research on Axsome Therapeutics. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Axsome Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.